Company news
Percheron Therapeutics Limited news in 2016
Percheron Therapeutics Limited's news releases, calls and decks from 2016, newest first.
Appendix 3C
December 7, 2016
Bonus and New Options Offer Prospectus
November 28, 2016
ATL1102 for Multiple Sclerosis - Progress Update
November 3, 2016
Capital Management Initiatives - Update
October 11, 2016
ATL1103 Higher Dose Study
October 10, 2016
Company Update
August 25, 2016
Positive Results Achieved from ATL1103 Higher Dose Study
July 26, 2016
ATL1103 Granted Orphan Drug Designation in Europe
June 27, 2016
ATL1102 for Multiple Sclerosis - Update
June 17, 2016
Antisense Technology Update
June 1, 2016
Company Strategy Update
May 23, 2016
Orphan Drug designation from FDA for ATL1103 in Acromegaly
May 12, 2016
ATL1103 Higher Dose Study - Update
May 9, 2016
ATL1103 Deed of Settlement, Termination and Transfer
April 29, 2016
ATL1102 for MS FDA Response to Phase IIb Study Plans
March 30, 2016
COR-004/ATL1103 Project Update
March 8, 2016
ATL1103 Data Presentation at Scientific Conference
February 11, 2016
ANP Licensing Partner Strongbridge Announces Pricing of IPO
February 10, 2016